Charles River Laboratories Intl. Inc vs D Wave Quantum Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.44 (market cap $14.23B), while D Wave Quantum Inc trades at $14.55 (market cap $5.54B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.6× D Wave Quantum Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and D Wave Quantum Inc for 32 Days on average.
| CRL | QBTS | |
|---|---|---|
Market Cap | $14.23B | $5.54B |
Volume | 1,176,885 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $310.77 | $44.78 |
52-Week Low | $149.93 | $12.98 |
Typical Hold Time | 33 Days | 32 Days |
Enterprise Value | $17.06B | $5.04B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
D-Wave Quantum (QBTS) trades at $14.52, down 4.6% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355 million in 2025 on $25 million in revenue, with a deeply negative net income margin. However, all 13 analysts covering the stock maintain a Buy rating with a consensus price target of $34.38, suggesting significant upside potential from current levels.
The outlook is highly speculative, balancing substantial analyst optimism against severe financial losses and ongoing securities investigations. Investment opportunity hinges on the company's ability to commercialize quantum technology, but risks include cash burn, competitive pressures, and legal uncertainties that could impede shareholder value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →